{"id":4554,"date":"2017-11-30T15:12:56","date_gmt":"2017-11-30T15:12:56","guid":{"rendered":"https:\/\/maat.swebwp.oci.eu\/?p=4554"},"modified":"2023-09-25T14:03:12","modified_gmt":"2023-09-25T14:03:12","slug":"maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer","status":"publish","type":"post","link":"https:\/\/maat.swebwp.oci.eu\/fr\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/","title":{"rendered":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer"},"content":{"rendered":"[vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]\n<h4><strong>MaaT Pharma To Release First in Patients Data At The 2017 ASH Meeting On Autologous Fecal Microbiota Transfer And Restoration Of Microbiota Diversity<\/strong><\/h4>\n<p><strong><em>The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.<\/em><\/strong><\/p>\n<p>(Lyon-France) &#8211; November 30, 2017 &#8211; MaaT Pharma, a French-based microbiome company developing innovative treatments for unmet medical needs in hematology-oncology, infection diseases and immune diseases such as GvHD, announces that data related to MaaT011* will be the subject of one poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition on December 9-12 in Atlanta, USA.<\/p>\n<p><em>*Product: Enema administration of MaaT011, Autologous Fecal Microbiota suspension, targeting diversity<\/em><br \/>\n<em>restoration following iatrogenic dysbiosis.<\/em>[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]The presentation details are as follows:<\/p>\n<ul>\n<li>Abstract Title: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive \/ Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial<\/li>\n<li>Date: Sunday, December 10, 2017, 6:00 PM-8:00 PM<\/li>\n<li>Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)<\/li>\n<li>Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II<\/li>\n<li>Presented by: Dr Florent Malard1 &amp; Dr Emilie Plantamura2<\/li>\n<li>Abstract: #2624<\/li>\n<li>Link: https:\/\/ash.confex.com\/ash\/2017\/webprogram\/Paper102744.html<\/li>\n<\/ul>\n<p>This presentation underlines the medical rationale of the use of FMT in hematology-oncology. The design of the ongoing Phase I\/II study, in Acute Myeloid Leukemia will also be explained.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_single_testimonial testimonial_style=\u00a0\u00bbsmall_modern\u00a0\u00bb color=\u00a0\u00bbDefault\u00a0\u00bb quote=\u00a0\u00bb\u201cOur metagenomic data show a huge impact of induction chemotherapy and antibiotics on microbiome with dramatic reduction of diversity at genus and species levels and significant increase of the antibiotic resistance gene copy-count.\u201d\u00a0\u00bb name=\u00a0\u00bbHerv\u00e9 Affagard, MaaT Pharma CEO.\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]Auto-FMT induced a recovery of microbiota diversity as high as 90% at the genus level and a return to the baseline of the resistance gene copy-count. A safety review by an external Data Safety Monitoring Board (DSMB) recently confirmed the safety profile of the product in this very fragile patient population.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_single_testimonial testimonial_style=\u00a0\u00bbsmall_modern\u00a0\u00bb color=\u00a0\u00bbDefault\u00a0\u00bb quote=\u00a0\u00bb\u201cThe microbiota comprehension enters an amazing and exciting new era of knowledge. Our capabilities in developing FMT-based product could open enormous potentialities to treat unmet medical needs. Presentation of these results at ASH annual meeting supports the Proof Of Concept of the first stage of MaaT Pharma\u2019s development strategy to treat dysbiosis-related diseases with an FMT based product.\u201d\u00a0\u00bb name=\u00a0\u00bbDavid Salako, Therapeutic Development Director at MaaT Pharma.\u00a0\u00bb][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][vc_column_text]Patients\u2019 profiles are currently being reviewed to assess clinical outcomes.<\/p>\n<h4>Microbiome research, an Investment for the Future<\/h4>\n<p>Recent findings in microbiome research are promising and open new therapeutic pathways for physicians and patients in infectious diseases, cancer, immuno-deficient diseases, obesity, autism, etc. Meanwhile, scientific publications and investments in biotech companies specialized in the microbiome have multiplied.<br \/>\nFor example, the United States has chosen to launch in 2016 \u00ab\u00a0The National Microbiome Initiative\u00a0\u00bb with a fund of more than $120 million for research. France also supports biotech companies like MaaT Pharma in this field, through its PIA investment program. MaaT Pharma is the first MicrobioTech to use GMP Compliant Fecal Microbiota Transfers (FMT) in patients.<\/p>\n<p>Following its Proof of Concept using MaaT011, MaaT Pharma currently develops drug products using autologous and allogeneic microbiota transfers. Driven by its exponential growth, MaaT Pharma has teamed up with Biocodex to develop an oral form of its drug. A step further towards industrialization of FMT for this MicrobioTech company, which has developed the first CE marked device for stool collection and dilution.[\/vc_column_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_highlighted_text color_type=\u00a0\u00bbregular\u00a0\u00bb highlight_color=\u00a0\u00bb#f2c836&Prime; style=\u00a0\u00bbhalf_text\u00a0\u00bb]\n<h3><em>About MaaT Pharma<\/em><\/h3>\n<p>Founded at the end of 2014, MaaT Pharma (Microbiota as a Therapy), a microbiome\u2013based biopharmaceutical company, revolutionizing and shaping a selective approach to therapies in order to treat debilitating diseases linked to gut microbiota imbalances. Thanks to the \u20ac16 million in funding MaaT Pharma is currently developing a range of FMT products for patients suffering from hematology-oncology, infection diseases and immune diseases such as GvHD to optimize the success of the harsh medical treatment associated. MaaT Pharma\u2019s revolutionary and rapid approach plays a considerable part in the evolution of tailored treatment therapies.<\/p>\n<p>Thanks to a strong scientific and medical network, the company is increasing its partnerships with renowned institutions such as INRA, and Bioaster and is part of a consortium coordinated by Institut Gustave Roussy to improve the efficacy of immunotherapies. In the coming months, MaaT Pharma will significantly pursue its development programs in hematological and infectious indications and is preparing its next fundraising with the objective of launching an oral formulation of the FMT drug product by 2018.<\/p>\n<p>MaaT Pharma is backed by its investors who are experts in the Microbiome field and in technological developments:<br \/>\nSeventure, CM-CIC Innovations, Biocodex and INRA.<\/p>\n<p>For additional information, please visit www.maatpharma.com or follow us on Twitter @MaaT_Pharma.[\/nectar_highlighted_text][\/vc_column][\/vc_row][vc_row type=\u00a0\u00bbin_container\u00a0\u00bb full_screen_row_position=\u00a0\u00bbmiddle\u00a0\u00bb column_margin=\u00a0\u00bbdefault\u00a0\u00bb column_direction=\u00a0\u00bbdefault\u00a0\u00bb column_direction_tablet=\u00a0\u00bbdefault\u00a0\u00bb column_direction_phone=\u00a0\u00bbdefault\u00a0\u00bb scene_position=\u00a0\u00bbcenter\u00a0\u00bb text_color=\u00a0\u00bbdark\u00a0\u00bb text_align=\u00a0\u00bbleft\u00a0\u00bb row_border_radius=\u00a0\u00bbnone\u00a0\u00bb row_border_radius_applies=\u00a0\u00bbbg\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb shape_divider_position=\u00a0\u00bbbottom\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb][vc_column column_padding=\u00a0\u00bbno-extra-padding\u00a0\u00bb column_padding_tablet=\u00a0\u00bbinherit\u00a0\u00bb column_padding_phone=\u00a0\u00bbinherit\u00a0\u00bb column_padding_position=\u00a0\u00bball\u00a0\u00bb column_element_spacing=\u00a0\u00bbdefault\u00a0\u00bb background_color_opacity=\u00a0\u00bb1&Prime; background_hover_color_opacity=\u00a0\u00bb1&Prime; column_shadow=\u00a0\u00bbnone\u00a0\u00bb column_border_radius=\u00a0\u00bbnone\u00a0\u00bb column_link_target=\u00a0\u00bb_self\u00a0\u00bb gradient_direction=\u00a0\u00bbleft_to_right\u00a0\u00bb overlay_strength=\u00a0\u00bb0.3&Prime; width=\u00a0\u00bb1\/1&Prime; tablet_width_inherit=\u00a0\u00bbdefault\u00a0\u00bb tablet_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb phone_text_alignment=\u00a0\u00bbdefault\u00a0\u00bb bg_image_animation=\u00a0\u00bbnone\u00a0\u00bb border_type=\u00a0\u00bbsimple\u00a0\u00bb column_border_width=\u00a0\u00bbnone\u00a0\u00bb column_border_style=\u00a0\u00bbsolid\u00a0\u00bb][nectar_btn size=\u00a0\u00bblarge\u00a0\u00bb open_new_tab=\u00a0\u00bbtrue\u00a0\u00bb button_style=\u00a0\u00bbregular\u00a0\u00bb button_color_2=\u00a0\u00bbAccent-Color\u00a0\u00bb color_override=\u00a0\u00bb#5bc0cc\u00a0\u00bb icon_family=\u00a0\u00bbiconsmind\u00a0\u00bb text=\u00a0\u00bbSee More\u00a0\u00bb icon_iconsmind=\u00a0\u00bbiconsmind-Mouse-Pointer\u00a0\u00bb margin_top=\u00a0\u00bb50&Prime; url=\u00a0\u00bbhttps:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2021\/09\/PR_MaaTPharma_ASH2017.pdf\u00a0\u00bb][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[53],"class_list":{"0":"post-4554","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-communiques-de-presse-fr","8":"year_press-53"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.3.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-30T15:12:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-25T14:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer\",\"datePublished\":\"2017-11-30T15:12:56+00:00\",\"dateModified\":\"2023-09-25T14:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\"},\"wordCount\":1978,\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\",\"name\":\"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2017-11-30T15:12:56+00:00\",\"dateModified\":\"2023-09-25T14:03:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/maat.swebwp.oci.eu\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#website\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\/\/maat.swebwp.oci.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma","og_description":"The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.","og_url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/","og_site_name":"MaaT Pharma","article_published_time":"2017-11-30T15:12:56+00:00","article_modified_time":"2023-09-25T14:03:12+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#article","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer","datePublished":"2017-11-30T15:12:56+00:00","dateModified":"2023-09-25T14:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/"},"wordCount":1978,"publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/","url":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/","name":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer - MaaT Pharma","isPartOf":{"@id":"https:\/\/maat.swebwp.oci.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage"},"thumbnailUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2017-11-30T15:12:56+00:00","dateModified":"2023-09-25T14:03:12+00:00","breadcrumb":{"@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#primaryimage","url":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/maat.swebwp.oci.eu\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/maat.swebwp.oci.eu\/maat-pharma-to-release-first-in-patients-data-on-autologous-fecal-microbiota-transfer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/maat.swebwp.oci.eu\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma To Release First in Patients Data On Autologous Fecal Microbiota Transfer"}]},{"@type":"WebSite","@id":"https:\/\/maat.swebwp.oci.eu\/#website","url":"https:\/\/maat.swebwp.oci.eu\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/maat.swebwp.oci.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/maat.swebwp.oci.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/maat.swebwp.oci.eu\/#organization","name":"Maat Pharma","url":"https:\/\/maat.swebwp.oci.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/maat.swebwp.oci.eu\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/comments?post=4554"}],"version-history":[{"count":0,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/posts\/4554\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/media?parent=4554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/categories?post=4554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/tags?post=4554"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/category_press?post=4554"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/maat.swebwp.oci.eu\/fr\/wp-json\/wp\/v2\/year_press?post=4554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}